


Find known drug-drug interactions for your drug

Cortellis Drug Discovery Intelligence

In this guide you'll learn how to quickly assess the interactions around your drug of interest. Use case: you are designing a clinical study and need to be aware of reported interactions with your drug.

1. Use **Quick Search** to search for your drug of interest (e.g. Rivaroxaban) in the Drug-Drug interactions knowledge area.



2. In the results page, you'll find a table that lists all the drug-drug interactions that have been reported for your drug. Within the table, you can sort your results as needed by using the arrows on the column headers, for instance by **Prescription**.

Drug-Drug Interactions						
Prescription						
45	5	54	37	2	13	
Contraindicated	Not Recommended	Warning/Precaution	No Interaction	Beneficial	Undisclosed	
▼ Apply Filters Sort Expand all Showing 1-20 of 156 Drug-Drug Interactions records for "Rivaroxaban"						
Evaluated Entity	Interacting Entity	Interaction Type	Outcome	Prescription	Population / Study Model	
Rivaroxaban	Antiplatelet Therapy	Pharmacodynamics	Adverse Event/Toxicity	Warning/Precaution	Humans/Adult/Thromboembolism	View record
Rivaroxaban	Cytochrome P450 3A4 (CYP3A4) Inhibitors	Metabolic	Increased Pharmacokinetic Exposure (Adverse Event/Toxicity)	Warning/Precaution	Humans	View record
Rivaroxaban	Broad Substrate Specificity ATP-Binding Cassette Transporter ABCG2 (BCRP) Inhibitors	Pharmacokinetics (ADME)	Increased Pharmacokinetic Exposure (Adverse Event/Toxicity)	Warning/Precaution	Humans	View record
Rivaroxaban	Fluconazole	Metabolic	Increased Pharmacokinetic Exposure (Adverse Event/Toxicity)	Warning/Precaution	Humans/Male/Adult/Fasted	View record
Rivaroxaban	Verapamil hydrochloride	Pharmacokinetics (ADME)	Increased Pharmacokinetic Exposure (Adverse Event/Toxicity)	Warning/Precaution	Humans/Fed/Renal failure (Mild)	View record

E indicates the outcome is supported by experimental results. A lack of **E** indicates the outcome is anticipated but there is no direct observation reported.

- Click on **View record** to know the details behind a specific interaction. In the example below, Verapamil hydrochloride inhibits ABCB1 (isoform 1) and CYP3A4 (isoform 1) [*Protein/Action*], causing increased pharmacokinetic exposure [*Outcome*] of Rivaroxaban [*Evaluated Entity*]. This can result in elevated prothrombin time and bleeding [*Adverse Events*]. For this reason, there is a warning [*Prescription*] in the source document [*Patent*].

Rivaroxaban ↔ Verapamil hydrochloride

Interaction ☆ ...

General information

Prescribing Details

Dose adjustment would be needed
Dose adjustment would be needed. Higher risk of bleeding is expected in patients with renal failure than in normal renal function.

Evaluated Entity: Rivaroxaban Evaluated Entity Type: Product

Prescription: Warning/Precaution

Related Content

- 🔍 Drugs & Biologics 2
- 🧬 Genes & Targets 2
- 📊 Pharmacokinetics 103
- 📄 Patents 1

Interaction Details

Interacting Entity	Interacting Entity Type	Interaction Type	Protein/Action	Strength
Verapamil hydrochloride	Product	Pharmacokinetics (ADME)	ATP-dependent translocase ABCB1 isoform 1 Inhibition Cytochrome P450 3A4 (isoform 1) Inhibition	

Outcome information

Population: Humans/Fed

Outcome: Increased Pharmacokinetic Exposure (Adverse Event/Toxicity) Outcome Validity: Supported by Experiments

Available Since: Dec 16, 2020 Adverse Events: Bleeding

Go to associated **Pharmacokinetics** records to compare all experiments from the same source, both alone and in co-administration.

For more information contact Customer Service at [LS Product Support](#)